Molecular and genetic aspects of the kallikrein-kinin system

Kinins

Volumn , Issue , 2011, Pages 7-32

  Alhenc Gelas, François ^a   Girolami, Jean Pierre ^b  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b Université de Toulouse   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881716059     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1515/9783110252354     Document Type: Chapter

References (166)

1. Abadir, P.M., Periasamy, A., Carey, R.M., and Siragy, H.M. (2006). Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension 48, 316-322.
2. Adam, A., Cugno, M., Molinaro, G., Perez, M., Lepage, Y., and Agostoni, A. (2002). Amino-peptidase P in individuals with a history of angiooedema on ACE inhibitors. Lancet 359, 2088-2089.
3. Alhenc-Gelas, F., and Corvol, P. (2000). Molecular and physiological aspects of angiotensin I-converting enzyme. In Handbook of Physiology, vol. III Section 7 (ed. J.S. Fray), 81-103. New York: American Physiological Society and Oxford University Press.
4. Alhenc-Gelas, F., Baussant, T., Hubert, C., Soubrier, F., and Corvol, P. (1989). The angiotensin converting enzyme in the kidney. J. Hypertens. Suppl. 7, S9-13; discussion S14.
5. Alhenc-Gelas, F., Bouby, N., Richer, C., Potier, L., Roussel, R., and Marre M. (2011). Kinins as therapeutic agents in cardiovascular and renal diseases. Curr. Pharm. Des. (in press).
6. Alhenc-Gelas, F., Marchetti, J., Allegrini, J., Corvol, P., and Menard, J. (1981). Measurement of urinary kallikrein activity: species differences in kinin production. Biochim. Biophys. Acta
7. Alhenc-Gelas, F., Richard, J., Courbon, D., Warnet, J.M., and Corvol, P. (1991). Distribution of plasma angiotensin I-converting enzyme levels in healthy men: relationship to environmental and hormonal parameters. J. Lab. Clin. Med. 117, 33-39.
8. Austinat, M., Braeuninger, S., Pesquero, J.B., Brede, M., Bader, M., Stoll, G., Renne, T., and Kleinschnitz, C. (2009). Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke 40, 285-293.
9. Azizi, M., Boutouyrie, P., Bissery, A., Agharazii, M., Verbeke, F., Stern, N., Bura-Riviere, A., Laurent, S., Alhenc-Gelas, F., and Jeunemaitre, X. (2005). Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J. Clin. Invest. 115, 780-787.
10. Azizi, M., Emanueli, C., Peyrard, S., Maddedu, P., Alhenc-Gelas, F., and Campbell, D.J. (2008). Genetic and dietary control of plasma tissue kallikrein secretion and urinary kinins excretion in man. J. Hypertens. 26, 714-720.
11. Azizi, M., Rousseau, A., Ezan, E., Guyene, T.T., Michelet, S., Grognet, J.M., Lenfant, M., Corvol, P., and Menard, J. (1996). Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J. Clin. Invest. 97, 839-844.
12. Beaubien, G., Rosinski-Chupin, I., Mattei, M.G., Mbikay, M., Chretien, M., and Seidah, N.G. (1991). Gene structure and chromosomal localization of plasma kallikrein. Biochemistry 30, 1628-1635.
13. Bergaya, S., Hilgers, R.H., Meneton, P., Dong, Y., Bloch-Faure, M., Inagami, T., Alhenc-Gelas, F., Levy, B.I., and Boulanger, C.M. (2004). Flow-dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors. Circ. Res. 94, 1623-1629.
14. Bergaya, S., Meneton, P., Bloch-Faure, M., Mathieu, E., Alhenc-Gelas, F., Levy, B.I., and Boulanger, C.M. (2001). Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice. Circ. Res. 88, 593-599.
15. Bernstein, K.E., Martin, B.M., Edwards, A.S., and Bernstein, E.A. (1989). Mouse angiotensin-converting enzyme is a protein composed of two homologous domains. J. Biol. Chem. 264, 11945-11951.
16. Berry, T.D., Hasstedt, S.J., Hunt, S.C., Wu, L.L., Smith, J.B., Ash, K.O., Kuida, H., and Williams, R.R. (1989). A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 13, 3-8.
17. Bodin, S., Chollet, C., Goncalves-Mendes, N., Gardes, J., Pean, F., Heudes, D., Bruneval, P., Marre, M., Alhenc-Gelas, F., and Bouby, N. (2009). Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney Int. 76, 395-403.
18. Boright, A.P., Paterson, A.D., Mirea, L., Bull, S.B., Mowjoodi, A., Scherer, S.W., and Zinman, B. (2005). Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes 54, 1238-1244.
19. Borkowski, J.A., Ransom, R.W., Seabrook, G.R., Trumbauer, M., Chen, H., Hill, R.G., Strader, C.D., and Hess, J.F. (1995). Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J. Biol. Chem. 270, 13706-13710.
20. Bossi, F., Fischetti, F., Regoli, D., Durigutto, P., Frossi, B., Gobeil, F., Jr., Ghebrehiwet, B., Peerschke, E.I., Cicardi, M., and Tedesco, F. (2009). Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J. Allergy Clin. Immunol. 124, 1303-1310 e4.
21. Bralet, J., and Schwartz, J.C. (2001). Vasopeptidase inhibitors: an emerging class of cardiovascular drugs. Trends Pharmacol. Sci. 22, 106-109.
22. Brillard-Bourdet, M., Moreau, T., and Gauthier, F. (1995). Substrate specificity of tissue kallikreins: importance of an extended interaction site. Biochim. Biophys. Acta 1246, 47-52.
23. Brown, N.J., Gainer, J.V., Murphey, L.J., and Vaughan, D.E. (2000). Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptordependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 102, 2190-2196.
24. Cambien, F., Alhenc-Gelas, F., Herbeth, B., Andre, J.L., Rakotovao, R., Gonzales, M.F., Allegrini, J., and Bloch, C. (1988). Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study. Am. J. Hum. Genet. 43, 774-780.
25. Cambien, F., Costerousse, O., Tiret, L., Poirier, O., Lecerf, L., Gonzales, M.F., Evans, A., Arveiler, D., Cambou, J.P., Luc, G., Rakotovao, R. Ducimetiere, P., Soubrier, F., and Alhenc-Gelas F. (1994). Plasma-level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial-infarction. Circulation 90, 669-676.
26. Cambien, F., Poirier, O., Lecerf, L., Evans, A., Cambou, J.P., Arveiler, D., Luc, G., Bard, J.M., Bara, L., Ricard S., Tiret, L., Amouyel, P., Alhenc-Gelas, F., and Soubrier, F. (1992). Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial-infarction. Nature 359, 641-644.
27. Campbell, D.J., Kladis, A., and Duncan, A.M. (1994). Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23, 439-449.
28. Campbell, W.B., Gebremedhin, D., Pratt, P.F., and Harder, D.R. (1996). Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res. 78, 415-423.
29. Cao, D.J., Guo, Y.L., and Colman, R.W. (2004). Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells. Circ. Res. 94, 1227-1234.
30. Cardoso, C.C., Garrett, T., Cayla, C., Meneton, P., Pesquero, J.B., and Bader, M. (2004). Structure and expression of two kininogen genes in mice. Biol. Chem. 385, 295-301.
31. Carson, J.A., and Turner, A.J. (2002). Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J. Neurochem. 81, 1-8.
32. Cayla, C., Merino, V.F., Cabrini, D.A., Silva, J.A., Jr., Pesquero, J.B., and Bader, M. (2002). Structure of the mammalian kinin receptor gene locus. Int. Immunopharmacol. 2, 1721-1727.
33. Cayla, C., Todiras, M., Iliescu, R., Saul, V.V., Gross, V., Pilz, B., Chai, G., Merino, V.F., Pesquero, J.B., Baltatu, O.C., and Bader M. (2007). Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J. 21 , 1689-1698.
34. Chai, K.X., Ward, D.C., Chao, J., and Chao, L. (1994). Molecular cloning, sequence analysis, and chromosomal localization of the human protease inhibitor 4 (kallistatin) gene (PI4). Genomics 23, 370-378.
35. Chao, J., Stallone, J.N., Liang, Y.M., Chen, L.M., Wang, D.Z., and Chao, L. (1997). Kallistatin is a potent new vasodilator. J. Clin. Invest. 100, 11-17.
36. Chavanas, S., Bodemer, C., Rochat, A., Hamel-Teillac, D., Ali, M., Irvine, A.D., Bonafe, J.L., Wilkinson, J., Taieb, A., Barrandon Y., Harper, J.I., de Prost, Y., and Hovnanian, A. (2000). Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet. 25, 141-142.
37. Chen, L.M., Chung, P., Chao, S., Chao, L., and Chao, J. (1992). Differential regulation of kininogen gene expression by estrogen and progesterone in vivo. Biochim. Biophys. Acta 1131 , 145-151.
38. Cheung, P.P., Cannizzaro, L.A., and Colman, R.W. (1992). Chromosomal mapping of human kininogen gene (KNG) to 3q26----qter. Cytogenet. Cell Genet. 59, 24-26.
39. Cheung, P.P., Kunapuli, S.P., Scott, C.F., Wachtfogel, Y.T., and Colman, R.W. (1993). Genetic basis of total kininogen deficiency in Williams' trait. J. Biol. Chem. 268, 23361-23365.
40. Chung, D.W., Fujikawa, K., McMullen, B.A., and Davie, E.W. (1986). Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 25, 2410-2417.
41. Clements, J.A. (2008). Reflections on the tissue kallikrein and kallikrein-related peptidase family - from mice to men - what have we learnt in the last two decades? Biol. Chem. 389, 1447-1454.
42. Clements, J.A., Fuller, P.J., McNally, M., Nikolaidis, I., and Funder, J.W. (1986). Estrogen regulation of kallikrein gene expression in the rat anterior pituitary. Endocrinology 119, 268-273.
43. Colman, R.W., Jameson, B.A., Lin, Y., Johnson, D., and Mousa, S.A. (2000). Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 95, 543-550.
44. Colman, R.W., and Schmaier, A.H. (1986). The contact activation system: biochemistry and interactions of these surface-mediated defense reactions. Crit. Rev. Oncol. Hematol. 5, 57-85.
45. Costacou, T., Chang, Y., Ferrell, R.E., and Orchard, T.J. (2006). Identifying genetic susceptibilities to diabetes-related complications among individuals at low risk of complications: an application of tree-structured survival analysis. Am. J. Epidemiol. 164, 862-872.
46. Costerousse, O., Allegrini, J., Clozel, J.P., Menard, J., and Alhenc-Gelas, F. (1998). Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia. J. Pharmacol. Exp. Ther. 284, 1180-1187.
47. Costerousse, O., Allegrini, J., Lopez, M., and Alhenc-Gelas, F. (1993). Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem. J. 290 (Pt 1), 33-40.
48. D'Adamio, L., Shipp, M.A., Masteller, E.L., and Reinherz, E.L. (1989). Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5' untranslated regions. Proc. Natl. Acad. Sci. USA 86, 7103-7107.
49. Danilov, S., Jaspard, E., Churakova, T., Towbin, H., Savoie, F., Wei, L., and Alhenc-Gelas, F. (1994). Structure-function analysis of angiotensin I-converting enzyme using monoclonal antibodies. Selective inhibition of the amino-terminal active site. J. Biol. Chem. 269, 26806-26814.
50. Danser, A.H., Schalekamp, M.A., Bax, W.A., van den Brink, A.M., Saxena, P.R., Riegger, G.A., and Schunkert, H. (1995). Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 92, 1387-1388.
51. Deddish, P.A., Marcic, B., Jackman, H.L., Wang, H.Z., Skidgel, R.A., and Erdos, E.G. (1998). N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension 31 , 912-917.
52. Diamandis, E.P., Yousef, G.M., Clements, J., Ashworth, L.K., Yoshida, S., Egelrud, T., Nelson, P.S., Shiosaka, S., Little, S., Lilja, H., Stenman, U.H., Rittenhouse, H.G., and Wain, H. (2000). New nomenclature for the human tissue kallikrein gene family. Clin. Chem. 46, 1855-1858.
53. Dias, J.P., Talbot, S., Senecal, J., Carayon, P., and Couture, R.(2010). Kinin B1 receptor enhances the oxidative stress in a rat model of insulin resistance: outcome in hypertension, allodynia and metabolic complications. PLoS One 5, e12622.
54. Dive, V., Cotton, J., Yiotakis, A., Michaud, A., Vassiliou, S., Jiracek, J., Vazeux, G., Chauvet, M.T., Cuniasse, P., and Corvol, P. (1999). RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc. Natl. Acad. Sci. USA 96, 4330-4335.
55. Duan, Q.L., Nikpoor, B., Dube, M.P., Molinaro, G., Meijer, I.A., Dion, P., Rochefort, D., Saint-Onge, J., Flury, L., Brown, N.J., Gainer, J.V., Rouleau, J.L., Agostoni, A., Cugno, M., Simon, P., Clavel, P., Potier, J., Wehbe, B., Benarbia, S., Marc-Aurele, J., Chanard, J., Foroud, T., Adam, A., and Rouleau, G.A. (2005). A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am. J. Hum. Genet. 77, 617-626.
56. Duchene, J., Cayla, C., Vessillier, S., Scotland, R., Yamashiro, K., Lecomte, F., Syed, I., Vo, P., Marrelli, A., Pitzalis, C., Cipollone, F., Schanstra, J., Bascands, J.L., Hobbs, A.J., Perretti, M., and Ahluwalia, A. (2009). Laminar shear stress regulates endothelial kinin B1 receptor expression and function: potential implication in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 29, 1757-1763.
57. Duka, I., Kintsurashvili, E., Gavras, I., Johns, C., Bresnahan, M., and Gavras, H. (2001). Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. Circ. Res. 88, 275-281.
58. Earle, K., Walker, J., Hill, C., and Viberti, G. (1992). Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N. Engl. J. Med. 326, 673-677.
59. El-Dorry, H.A., Pickett, C.B., MacGregor, J.S., and Soffer, R.L. (1982). Tissue-specific expression of mRNAs for dipeptidyl carboxypeptidase isoenzymes. Proc. Natl. Acad. Sci. USA 79, 4295-4297.
60. Erdos, E.G. (1990). Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture. Hypertension 16, 363-370.
61. Eyries, M., Agrapart, M., Alonso, A., and Soubrier, F. (2002). Phorbol ester induction of angiotensin-converting enzyme transcription is mediated by Egr-1 and AP-1 in human en-dothelial cells via ERK1/2 pathway. Circ. Res. 91, 899-906.
62. Fleming, I. (2006). Signaling by the angiotensin-converting enzyme. Circ. Res. 98, 887-896.
63. Fournie-Zaluski, M.C., Gonzalez, W., Turcaud, S., Pham, I., Roques, B.P., and Michel, J.B. (1994). Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. Proc. Natl. Acad. Sci. USA 91, 4072-4076.
64. Fuchs, S., Xiao, H.D., Hubert, C., Michaud, A., Campbell, D.J., Adams, J.W., Capecchi, M. R., Corvol, P., and Bernstein, K.E. (2008). Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 51, 267-274.
65. Furchgott, R.F., and Vanhoutte, P.M. (1989). Endothelium-derived relaxing and contracting factors. FASEB J. 3, 2007-2018.
66. Greenbaum, L.M. (1992). The T-kininogen, T-kinin system of the rat. Agents Actions Suppl.36, 215-222.
67. Griol-Charhbili, V., Messadi-Laribi, E., Bascands, J.L., Heudes, D., Meneton, P., Giudicelli, J.F., Alhenc-Gelas, F., and Richer, C. (2005). Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J. 19, 1172-1174.
68. Haberbosch, W., Bohle, R.M., Franke, F.E., Danilov, S., Alhenc-Gelas, F., Braun-Dullaeus, R., Holschermann, H., Waas, W., Tillmanns, H., and Gardemann, A. (1997). The expression of angiotensin I-converting enzyme in human atherosclerotic plaques is not related to the deletion/insertion polymorphism but to the risk of restenosis after coronary interventions. Atherosclerosis 130, 203-213.
69. Haddad, E.B., Fox, A.J., Rousell, J., Burgess, G., McIntyre, P., Barnes, P.J., and Chung, K.F. (2000). Post-transcriptional regulation of bradykinin B1 and B2 receptor gene expression in human lung fibroblasts by tumor necrosis factor-alpha: modulation by dexamethasone. Mol. Pharmacol. 57, 1123-1131.
70. Hadjadj, S., Belloum, R., Bouhanick, B., Gallois, Y., Guilloteau, G., Chatellier, G., Alhenc-Gelas, F., and Marre, M. (2001). Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. J. Am. Soc. Nephrol. 12, 541-549.
71. Hagaman, J.R., Moyer, J.S., Bachman, E.S., Sibony, M., Magyar, P.L., Welch, J.E., Smithies, O., Krege, J.H., and O'Brien, D.A. (1998). Angiotensin-converting enzyme and male fertility. Proc. Natl. Acad. Sci. USA 95, 2552-2557.
72. Harvey, T.J., Hooper, J.D., Myers, S.A., Stephenson, S.A., Ashworth, L.K., and Clements, J. A. (2000). Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J. Biol. Chem. 275, 37397-37406.
73. Hasan, A.A., Cines, D.B., Ngaiza, J.R., Jaffe, E.A., and Schmaier, A.H. (1995). High-molecular-weight kininogen is exclusively membrane bound on endothelial cells to influence activation of vascular endothelium. Blood 85, 3134-3143.
74. Hecker, M., Bara, A.T., Bauersachs, J., and Busse, R. (1994). Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J. Physiol. 481 (Pt 2), 407-414.
75. Hecquet, C., Tan, F., Marcic, B.M., and Erdos, E.G. (2000). Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases. Mol. Pharmacol. 58, 828-836.
76. Herwald, H., Renne, T., Meijers, J.C., Chung, D.W., Page, J.D., Colman, R.W., and Muller-Esterl, W. (1996). Mapping of the discontinuous kininogen binding site of prekallikrein. A distal binding segment is located in the heavy chain domain A4. J. Biol. Chem. 271 , 13061-13067.
77. Hilgenfeldt, U., Stannek, C., Lukasova, M., Schnolzer, M., and Lewicka, S. (2005). Rat tissue kallikrein releases a kallidin-like peptide from rat low-molecular-weight kininogen. Br. J. Pharmacol. 146, 958-963.
78. Hirsch, A.T., Talsness, C.E., Schunkert, H., Paul, M., and Dzau, V.J. (1991). Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ. Res. 69, 475-482.
79. Hojima, Y., Isobe, M., and Moriya, H. (1977). Kallikrein inhibitors in rat plasma. J. Biochem. 81 , 37-46.
80. Huang, W., Gallois, Y., Bouby, N., Bruneval, P., Heudes, D., Belair, M.F., Krege, J.H., Meneton, P., Marre, M., Smithies, O., and Alhenc-Gelas, F. (2001). Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc. Natl. Acad. Sci. USA 98, 13330-13334.
81. Hubert, C., Houot, A.M., Corvol, P., and Soubrier, F. (1991). Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. J. Biol. Chem. 266, 15377-15383.
82. Jaffa, A.A., Durazo-Arvizu, R., Zheng, D., Lackland, D.T., Srikanth, S., Garvey, W.T., and Schmaier, A.H. (2003). Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes 52, 1215-1221.
83. Jaspard, E., Wei, L., and Alhenc-Gelas, F. (1993). Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J. Biol. Chem. 268, 9496-9503.
84. Juillerat, L., Nussberger, J., Menard, J., Mooser, V., Christen, Y., Waeber, B., Graf, P., and Brunner, H.R. (1990). Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 16, 564-572.
85. Kakoki, M., Kizer, C.M., Yi, X., Takahashi, N., Kim, H.S., Bagnell, C.R., Edgell, C.J., Maeda, N., Jennette, J.C., and Smithies, O. (2006). Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J. Clin. Invest. 116, 1302-1309.
86. Kakoki, M., McGarrah, R.W., Kim, H.S., and Smithies, O. (2007). Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc. Natl. Acad. Sci. USA 104, 7576-7581.
87. Katz, B.A., Liu, B., Barnes, M., and Springman, E.B. (1998). Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution. Protein Sci. 7, 875-885.
88. Keil, C., Maskos, K., Than, M., Hoopes, J.T., Huber, R., Tan, F., Deddish, P.A., Erdos, E.G., Skidgel, R.A., and Bode, W. (2007). Crystal structure of the human carboxypeptidase N (kininase I) catalytic domain. J. Mol. Biol. 366, 504-516.
89. Kitamura, N., Kitagawa, H., Fukushima, D., Takagaki, Y., Miyata, T., and Nakanishi, S. (1985). Structural organization of the human kininogen gene and a model for its evolution. J. Biol. Chem. 260, 8610-8617.
90. Kohlstedt, K., Gershome, C., Friedrich, M., Muller-Esterl, W., Alhenc-Gelas, F., Busse, R. and Fleming, I. (2006). Angiotensin-converting enzyme (ACE) dimerization is the initial step in the ACE inhibitor-induced ACE signaling cascade in endothelial cells. Mol. Pharmacol. 69, 1725-1732.
91. Kohlstedt, K., Gershome, C., Trouvain, C., Hofmann, W.K., Fichtlscherer, S., and Fleming, I. (2009). Angiotensin-converting enzyme (ACE) inhibitors modulate cellular retinol-binding protein 1 and adiponectin expression in adipocytes via the ACE-dependent signaling cascade. Mol. Pharmacol. 75, 685-692.
92. Krege, J.H., John, S.W., Langenbach, L.L., Hodgin, J.B., Hagaman, J.R., Bachman, E.S., Jennette, J.C., O'Brien, D.A., and Smithies, O. (1995). Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 375, 146-148.
93. Krege, J.H., Kim, H.S., Moyer, J.S., Jennette, J.C., Peng, L., Hiller, S.K., and Smithies, O. (1997). Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension 29, 150-157.
94. Lachurie, M.L., Azizi, M., Guyene, T.T., Alhenc-Gelas, F., and Menard, J. (1995). Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 91 , 2933-2942.
95. Lalmanach, G., Naudin, C., Lecaille, F., and Fritz, H. (2010). Kininogens: more than cysteine protease inhibitors and kinin precursors. Biochimie 92, 1568-1579.
96. Lattion, A.L., Soubrier, F., Allegrini, J., Hubert, C., Corvol, P., and Alhenc-Gelas, F. (1989). The testicular transcript of the angiotensin I-converting enzyme encodes for the ancestral, non-duplicated form of the enzyme. FEBS Lett. 252, 99-104.
97. Leeb-Lundberg, L.M., Marceau, F., Muller-Esterl, W., Pettibone, D.J., and Zuraw, B.L. (2005). International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 57, 27-77.
98. Linz, W., Wiemer, G., Gohlke, P., Unger, T., and Scholkens, B.A. (1995). Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 47, 25-49.
99. Liu, Y.H., Yang, X.P., Sharov, V.G., Nass, O., Sabbah, H.N., Peterson, E., and Carretero, O.A. (1997). Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J. Clin. Invest. 99, 1926-1935.
100. Marchetti, J., Imbert-Teboul, M., Alhenc-Gelas, F., Allegrini, J., Menard, J., and Morel, F. (1984). Kallikrein along the rabbit microdissected nephron: a micromethod for its measurement. Effect of adrenalectomy and DOCA treatment. Pflugers Arch. 401, 27-33.
101. Margolius, H.S. (1995). Theodore Cooper Memorial Lecture. Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension 26, 221-229.
102. Margolius, H.S., Horwitz, D., Geller, R.G., Alexander, R.W., Gill, J.R., Jr., Pisano, J.J., and Keiser, H.R. (1974). Urinary kallikrein excretion in normal man. Relationships to sodium intake and sodium-retaining steroids. Circ. Res. 35, 812-819.
103. Marin-Castano, M.E., Schanstra, J.P., Neau, E., Praddaude, F., Pecher, C., Ader, J.L., Girolami, J.P., and Bascands, J.L. (2002). Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation 105, 627-632.
104. Marre, M., Bernadet, P., Gallois, Y., Savagner, F., Guyene, T.T., Hallab, M., Cambien, F., Passa, P., and Alhenc-Gelas, F. (1994). Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 43, 384-388.
105. Marre, M., Jeunemaitre, X., Gallois, Y., Rodier, M., Chatellier, G., Sert, C., Dusselier, L., Kahal, Z., Chaillous, L., Halimi, S., Muller, A., Sackmann, H., Bauduceau, B., Bled, F., Passa, P., and Alhenc-Gelas, F. (1997). Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J. Clin. Invest. 99, 1585-1595.
106. Mathews, K.P., Pan, P.M., Gardner, N.J., and Hugli, T.E. (1980). Familial carboxypeptidase N deficiency. Ann. Intern. Med. 93, 443-445.
107. McKenzie, C.A., Abecasis, G.R., Keavney, B., Forrester, T., Ratcliffe, P.J., Julier, C., Connell, J.M., Bennett, F., McFarlane-Anderson, N., Lathrop, G.M., and Cardon, L.R. (2001). Transethnic fine mapping of a quantitative trait locus for circulating angiotensin I-converting enzyme (ACE). Hum. Mol. Genet. 10, 1077-1084.
108. Meneton, P., Bloch-Faure, M., Hagege, A. A., Ruetten, H., Huang, W., Bergaya, S., Ceiler, D., Gehring, D., Martins, I., Salmon, G. Boulanger, C.M., Nussberger, J., Crozatier, B., Gasc, J.M., Heudes, D., Bruneval, P., Doetschman, T., Menard, J., and Alhenc-Gelas, F. (2001). Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc. Natl. Acad Sci. USA 98, 2634-2639.
109. Merkulov, S., Zhang, W.M., Komar, A.A., Schmaier, A.H., Barnes, E., Zhou, Y., Lu, X., Iwaki, T., Castellino, F.J., Luo, G., and McCrae, K.R. (2008). Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 111, 1274-1281.
110. Messadi, E., Vincent, M.P., Griol-Charhbili, V., Mandet, C., Colucci, J., Krege, J.H., Bruneval, P., Bouby, N., Smithies, O., Alhenc-Gelas, F., and Richer, C. (2010). Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia. FASEB J. 24, 4691-4700.
111. Messadi-Laribi, E., Griol-Charhbili, V., Pizard, A., Vincent, M.P., Heudes, D., Meneton, P., Alhenc-Gelas, F., and Richer, C. (2007). Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia. J. Pharmacol. Exp. Ther.323, 210-216.
112. Metzger, R., Bohle, R.M., Chumachenko, P., Danilov, S.M., and Franke, F.E. (2000). CD143 in the development of atherosclerosis. Atherosclerosis 150, 21-31.
113. Metzger, R., Franke, F.E., Bohle, R.M., Alhenc-Gelas, F., and Danilov, S.M (2011). Heterogeneous distribution of angiotensin I-converting enzyme (CD143) in the human and rat vascular systems: Vessel, organ and species specificity. Microvasc. Res. 81, 206-215.
114. Milan, A., Mulatero, P., Williams, T.A., Carra, R., Schiavone, D., Martuzzi, R., Rabbia, F., and Veglio, F. (2005). Bradykinin B2 receptor gene (-58T/C) polymorphism influences baroreflex sensitivity in never-treated hypertensive patients. J. Hypertens. 23, 63-69.
115. Mueller-Ortiz, S.L., Wang, D., Morales, J.E., Li, L., Chang, J.Y., and Wetsel, R.A. (2009). Targeted disruption of the gene encoding the murine small subunit of carboxypeptidase N (CPN1) causes susceptibility to C5a anaphylatoxin-mediated shock. J. Immunol. 182, 6533-6539.
116. Murphey, L.J., Eccles, W.K., Williams, G.H., and Brown, N.J. (2004). Loss of sodium modulation of plasma kinins in human hypertension. J. Pharmacol. Exp. Ther. 308, 1046-1052.
117. Murphey, L.J., Gainer, J.V., Vaughan, D.E., and Brown, N.J. (2000). Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 102, 829-832.
118. Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., and Agostoni, A. (1998). Plasma bradykinin in angio-oedema. Lancet 351 , 1693-1697.
119. Parving, H.H., de Zeeuw, D., Cooper, M.E., Remuzzi, G., Liu, N., Lunceford, J., Shahinfar, S., Wong, P.H., Lyle, P.A., Rossing, P., and Brenner B.M. (2008). ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J. Am. Soc. Nephrol. 19, 771-779.
120. Picard, N., Eladari, D., El Moghrabi, S., Planes, C., Bourgeois, S., Houillier, P., Wang, Q., Burnier, M., Deschenes, G., Knepper, M.A., Meneton, P., and Chambrey, R. (2008). Defective ENaC processing and function in tissue kallikrein-deficient mice. J. Biol. Chem. 283, 4602-4611.
121. Picard, N., Van Abel, M., Campone, C., Seiler, M., Bloch-Faure, M., Hoenderop, J.G., Loffing, J., Meneton, P., Bindels, R.J., Paillard, M., Alhenc-Gelas, F., and Houillier, P. (2005). Tissue kallikrein-deficient mice display a defect in renal tubular calcium absorption. J. Am. Soc. Nephrol. 16, 3602-3610.
122. Plummer, T.H., Jr., and Erdos, E.G. (1981). Human plasma carboxypeptidase N. Methods Enzymol. 80 Pt C, 442-449.
123. Rakugi, H., Kim, D.K., Krieger, J.E., Wang, D.S., Dzau, V.J., and Pratt, R.E. (1994). Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. J. Clin. Invest. 93, 339-346.
124. Regoli, D.C., Marceau, F., and Lavigne, J. (1981). Induction of beta 1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur. J. Pharmacol. 71, 105-115.
125. Regoli, D., Rizzi, A., Perron, S.I., and Gobeil, F., Jr. (2001). Classification of kinin receptors. Biol. Chem. 382, 31-35.
126. Renne, T., Dedio, J., Meijers, J.C., Chung, D., and Muller-Esterl, W. (1999). Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2. J. Biol. Chem. 274, 25777-25784.
127. Richards, R.I., Holman, K., Shen, Y., Kozman, H., Harley, H., Brook, D., and Shaw, D. (1991). Human glandular kallikrein genes: genetic and physical mapping of the KLK1 locus using a highly polymorphic microsatellite PCR marker. Genomics 11, 77-82.
128. Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., and Soubrier, F. (1990). An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86, 1343-1346.
129. Rossi, G.P., Taddei, S., Ghiadoni, L., Virdis, A., Zavattiero, S., Favilla, S., Versari, D., Sudano, I., Azizi, M., Vedie, B., Pessina, A.C., Salvetti, A., and Jeunemaitre, X. (2006). Tissue kallikrein gene polymorphisms induce no change in endothelium-dependent or independent vasodilation in hypertensive and normotensive subjects. J. Hypertens 24, 1955-1963.
130. Rousseau, A., Michaud, A., Chauvet, M.T., Lenfant, M., and Corvol, P. (1995). The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J. Biol. Chem. 270, 3656-3661.
131. Sayed-Tabatabaei, F.A., Oostra, B.A., Isaacs, A., van Duijn, C.M., and Witteman, J.C. (2006). ACE polymorphisms. Circ. Res. 98, 1123-1133.
132. Schapira, M., de Agostini, A., and Colman, R.W. (1988). C1 inhibitor: the predominant inhibitor of plasma kallikrein. Methods Enzymol. 163, 179-185.
133. Schmaier, A.H. (2000). Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions. Curr. Opin. Hematol. 7, 261-265.
134. Schmaier, A.H., Bradford, H., Silver, L.D., Farber, A., Scott, C.F., Schutsky, D., and Colman, R.W. (1986). High molecular weight kininogen is an inhibitor of platelet calpain. J. Clin. Invest. 77, 1565-1573.
135. Schmaier, A.H., and McCrae, K.R. (2007). The plasma kallikrein-kinin system: its evolution from contact activation. J. Thromb. Haemost. 5, 2323-2329.
136. Scicli, A.G., Carbini, L.A., and Carretero, O.A. (1993). The molecular biology of the kallikrein-kinin system: II. The rat gene family. J. Hypertens. 11, 775-780.
137. Seaquist, E.R., Goetz, F.C., Rich, S., and Barbosa, J. (1989). Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N. Engl. J. Med.320, 1161-1165.
138. Shesely, E.G., Hu, C.B., Alhenc-Gelas, F., Meneton, P., and Carretero, O.A. (2006). A second expressed kininogen gene in mice. Physiol. Genomics 26, 152-157.
139. Shine, J., Mason, A.J., Evans, B.A., and Richards, R.I. (1983). The kallikrein multigene family: specific processing of biologically active peptides. Cold Spring Harb. Symp. Quant. Biol. 48 Pt 1, 419-426.
140. Siragy, H.M., de Gasparo, M., and Carey, R.M. (2000). Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 35, 1074-1077.
141. Siragy, H.M., Jaffa, A.A., Margolius, H.S., and Carey, R.M. (1996). Renin-angiotensin system modulates renal bradykinin production. Am. J. Physiol. 271 , R1090-1095.
142. Skidgel, R.A., and Erdos, E.G. (2007). Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator. Int. Immunopharmacol. 7, 1888-1899.
143. Slim, R., Torremocha, F., Moreau, T., Pizard, A., Hunt, S.C., Vuagnat, A., Williams, G.H., Gauthier, F., Jeunemaitre, X., and Alhenc-Gelas, F. (2002). Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. J. Am. Soc. Nephrol.13, 968-976.
144. Song, Q., Chao, J., and Chao, L. (1997). DNA polymorphisms in the 5'-flanking region of the human tissue kallikrein gene. Hum. Genet. 99, 727-734.
145. Soubrier, F., Alhenc-Gelas, F., Hubert, C., Allegrini, J., John, M., Tregear, G., and Corvol, P. (1988). Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc. Natl. Acad. Sci. USA 85, 9386-9390.
146. Stoves, J., Goode, N.P., Visvanathan, R., Jones, C.H., Shires, M., Will, E.J., and Davison, A.M. (2001). The bradykinin response and early hypotension at the introduction of continuous renal replacement therapy in the intensive care unit. Artif. Organs 25, 1009-1013. Takahashi, N., Hagaman, J.R., Kim, H.S., and Smithies, O. (2003). Minireview: computer simulations of blood pressure regulation by the renin-angiotensin system. Endocrinology144, 2184-2190.
147. Takahashi, N., Hagaman, J.R., Kim, H.S., and Smithies, O. (2003). Minireview: computer simulations of blood pressure regulation by the renin-angiotensin system. Endocrinology144, 2184-2190
148. Tang, J., Yu, C.L., Williams, S.R., Springman, E., Jeffery, D., Sprengeler, P.A., Estevez, A., Sam-pang, J., Shrader, W., Spencer, J., Young, W., McGrath, M., and Katz, B.A. (2005). Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein. J. Biol. Chem. 280, 41077-41089.
149. Tarnow, L., Groop, P.H., Hadjadj, S., Kazeem, G., Cambien, F., Marre, M., Forsblom, C., Parving, H.H., Tregouet, D., Thevard, A., Farrall, M., Gut, I., Gauguier, D., Cox, R., Matsuda, F., Lathrop, M., and Vionnet, N. (2008). European rational approach for the genetics of diabetic complications - EURAGEDIC: patient populations and strategy. Nephrol. Dial. Transplant 23, 161-168.
150. Tschope, C., Spillmann, F., Altmann, C., Koch, M., Westermann, D., Dhayat, N., Dhayat, S., Bascands, J.L., Gera, L., Hoffmann, S., Schultheiss, H.P., and Walther, T. (2004). The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction. Cardiovasc. Res. 61 , 559-569.
151. Tsutsumi, Y., Matsubara, H., Masaki, H., Kurihara, H., Murasawa, S., Takai, S., Miyazaki, M., Nozawa, Y., Ozono, R., Nakagawa, K., Miwa, T., Kawada, N., Mori, Y., Shibasaki, Y., Tanaka, Y., Fujiyama, S., Koyama, Y., Fujiyama, A., Takahashi, H., and Iwasaka, T. (1999). Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J. Clin. Invest. 104, 925-935.
152. Ura, N., Carretero, O.A., and Erdos, E.G. (1987). Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int. 32, 507-513.
153. Ward, P.E., Chow, A., and Drapeau, G. (1991). Metabolism of bradykinin agonists and antagonists by plasma aminopeptidase P. Biochem. Pharmacol. 42, 721-727.
154. Wei, L., Alhenc-Gelas, F., Corvol, P., and Clauser, E. (1991a). The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J. Biol. Chem. 266, 9002-9008.
155. Wei, L., Alhenc-Gelas, F., Soubrier, F., Michaud, A., Corvol, P., and Clauser, E. (1991b). Expression and characterization of recombinant human angiotensin I-converting enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes. J. Biol. Chem. 266, 5540-5546.
156. Wei, L., Clauser, E., Alhenc-Gelas, F., and Corvol, P. (1992). The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J. Biol. Chem. 267, 13398-13405.
157. Weiss, A.S., Gallin, J.I., and Kaplan, A.P. (1974). Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J. Clin. Invest. 53, 622-633.
158. Westermann, D., Walther, T., Savvatis, K., Escher, F., Sobirey, M., Riad, A., Bader, M., Schultheiss, H.P., and Tschope, C. (2009). Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes 58, 1373-1381.
159. Wuepper, K.D., Miller, D.R., and Lacombe, M.J. (1975). Flaujeac trait. Deficiency of human plasma kininogen. J. Clin. Invest. 56, 1663-1672.
160. Xu, J., Carretero, O.A., Shesely, E.G., Rhaleb, N.E., Yang, J.J., Bader, M., and Yang, X.P. (2009). The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice. Exp. Physiol. 94, 322-329.
161. Yousef, G.M., and Diamandis, E.P. (2001). The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 22, 184-204.
162. Yu, H., Bowden, D.W., Spray, B.J., Rich, S.S., and Freedman, B.I. (1998). Identification of human plasma kallikrein gene polymorphisms and evaluation of their role in end-stage renal disease. Hypertension 31, 906-911.
163. Zanchi, A., Maillard, M., and Burnier, M. (2003). Recent clinical trials with omapatrilat: new developments. Curr. Hypertens. Rep. 5, 346-352.
164. Zhao, A., Lew, J.L., Huang, L., Yu, J., Zhang, T., Hrywna, Y., Thompson, J.R., de Pedro, N., Blevins, R.A., Pelaez, F., Wright, S. D., and Cui, J (2003). Human kininogen gene is trans-activated by the farnesoid X receptor. J. Biol. Chem. 278, 28765-28770.
165. Zhou, G.X., Chao, L., and Chao, J. (1992). Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J. Biol. Chem. 267, 25873-25880.
166. Zinner, S.H., Margolius, H.S., Rosner, B., Keiser, H.R., and Kass, E.H. (1976). Familial aggregation of urinary kallikrein concentration in childhood: relation to blood pressure, race and urinary electrolytes. Am. J. Epidemiol. 104, 124-132.